Martela Corporation, Interim report, 12.5.2026, at 08:00 a.m. The revenue and operating result for January-March 2026 ...
Martela Corporation, Interim report, 12.5.2026, at 08:00 a.m. The revenue and operating result for January-March 2026 decreased compared to the same period of the previous year. January-March 2026 ...
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for ...
And it "should last a lifetime." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results